Physician profile
Lance E Robbins
NPI 1578863791
$5,194.78
in general payments reported to CMS, 2019-2025
23 companies · $2,653 in 2025
The $2,653 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $661 · 2023: $720 · 2024: $661 · 2025: $2,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Travel and Lodging: $664 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.93 |
| Travel and Lodging | $663.75 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,417.80 | 2021-2025 | Watchman, Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $680.66 | 2021-2025 | Lifevest |
| Pfizer INC. | $538.37 | 2022-2025 | |
| Amgen INC. | $434.73 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $404.07 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $325.90 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $301.13 | 2024-2025 | Pascal, Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $288.63 | 2023-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $171.98 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $104.31 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $96.73 | 2021-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $81.84 | 2021-2023 | |
| Esperion Therapeutics, INC. | $64.78 | 2023-2025 | Nexletol |
| Cvrx, INC. | $63.90 | 2022-2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.90 | 2022-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $27.25 | 2025 | Onpattro |
| Kestra Medical Technology Services, INC. | $22.61 | 2023 | Assure Wcd |
| Davol INC. | $20.51 | 2025 | Arista |
| Scpharmaceuticals INC. | $19.93 | 2025 | |
| Abiomed | $19.35 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $18.16 | 2023 | Inpefa |
| Philips North America LLC | $16.45 | 2024 | (Ck7) Extended Holter |
| Regeneron Healthcare Solutions, INC. | $14.79 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.